NCT00082940已完成2 期
A Phase II Study of ONTAK® (Denileukin Diftitox, DABIL-2) in Patients With Fludarabine-Refractory B-Cell Chronic Lymphocytic Leukemia
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 22
研究概览
简要总结
RATIONALE: Biological therapies, such as denileukin diftitox, may interfere with the growth of cancer cells and slow the growth of chronic lymphocytic leukemia.
PURPOSE: This phase II trial is studying how well denileukin diftitox works in treating patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
详细描述
OBJECTIVES:
Primary
- Determine the complete and partial response rate in patients with fludarabine-refractory B-cell chronic lymphocytic leukemia treated with denileukin diftitox.
Secondary
- Determine the toxicity profile of this drug in these patients.
- Determine the response rate in patients (regardless of CD25 receptor density) treated with this drug.
- Determine the progression-free survival and overall survival of patients treated with this drug.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 120 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究者
研究点 (22)
Loading locations...
相似试验
已完成
2 期
Denileukin Diftitox in Treating Patients With Relapsed or Refractory Non-Hodgkin's LymphomaLymphomaNCT00138164Jonsson Comprehensive Cancer Center50
Unknown
2 期
Denileukin Diftitox in Treating Patients With Non-Hodgkin's LymphomaLeukemiaLymphomaNCT00026429Pharmatech Oncology
已完成
1 期
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous TreatmentRecurrent Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast CancerMale Breast CancerNCT00425672University of Washington15
已完成
2 期
Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney CancerKidney CancerMelanoma (Skin)NCT00082914National Cancer Institute (NCI)
已完成
2 期
Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's LymphomaLymphomaNCT00460109Alliance for Clinical Trials in Oncology24